A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs

Study Identifier
P16-666
CT.gov Identifier
NCT03201718
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Hepatitis
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18 - 99 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Participants with type C hepatitis * Participants prescribed Viekira/Exviera in accordance with approved local label
    Exclusion Criteria:
    * None

    Protocol Summary

    Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.

    Study Locations

    Location
    Status
    Location
    Dong-A University Hospital /ID# 167362
    Busan, Busan Gwang Yeogsi, Republic of Korea, 49201
    Status
    Not applicable
    Location
    Pusan National University Hosp /ID# 167363
    Busan, Busan Gwang Yeogsi, Republic of Korea, 602-739
    Status
    Not applicable
    Location
    Kyungpook National Univ Hosp /ID# 168731
    Daegu, Daegu Gwang Yeogsi, Republic of Korea, 41944
    Status
    Not applicable
    Location
    Yeungnam University Med Ctr /ID# 167425
    Daegu, Daegu Gwang Yeogsi, Republic of Korea, 42415
    Status
    Not applicable
    Location
    Chungnam National University Hospital /ID# 167724
    Junggu, Daejeon Gwang Yeogsi, Republic of Korea, 35015
    Status
    Not applicable
    Location
    National health insurance cooperation ilsan hospital /ID# 201806
    Goyang, Gyeonggido, Republic of Korea, 10444
    Status
    Not applicable
    Showing {first} - {last} of {total} Results